Literature DB >> 17119546

Prevalence of the metabolic syndrome among Turkish adults.

O Kozan1, A Oguz, A Abaci, C Erol, Z Ongen, A Temizhan, S Celik.   

Abstract

OBJECTIVE: To determine prevalence of the metabolic syndrome (MS) in a sample representing Turkish population using United States Adult Treatment Panel-3 guidelines.
DESIGN: The study included random samples from both urban and rural populations in the seven geographical regions of Turkey. The population for this analysis were 2108 men (1372 in urban and 736 in rural areas) and 2151 women (1423 in urban and 728 in rural areas) with a mean age of 40.9+/-14.9 years (range 20-90).
RESULTS: The prevalence of the MS diagnosed using the Adult Treatment Panel III criteria was 33.9% (1442 of 4259) and differed significantly in men (28%) and women (39.6%). The prevalence of syndrome increased with age in men, from 10.7% in subjects aged 20-29 years to 49% in those aged over 70 years. The prevalence increased with age in women, from 9.6% in subjects aged 20-29 years to 74.6% in those aged 60-69 years, and decreased to 68.6% in those over 70 years of age. The prevalence of the syndrome was similar in urban (33.8%) and rural (33.9%) population. We found 26.8, 26.4, 19.3, 10.9 and 3.6% of the population had at least 1, 2, 3, 4 or 5 components, respectively. We found 57.2, 32.3 and 10.6% of the subjects with MS had 3, 4 and 5 components, respectively.
CONCLUSIONS: The prevalence of the MS in the adult Turkish population is very high, especially in women. Our findings have important implications for public health in Turkey.

Entities:  

Mesh:

Year:  2006        PMID: 17119546     DOI: 10.1038/sj.ejcn.1602554

Source DB:  PubMed          Journal:  Eur J Clin Nutr        ISSN: 0954-3007            Impact factor:   4.016


  36 in total

Review 1.  The metabolic syndrome.

Authors:  Marc-Andre Cornier; Dana Dabelea; Teri L Hernandez; Rachel C Lindstrom; Amy J Steig; Nicole R Stob; Rachael E Van Pelt; Hong Wang; Robert H Eckel
Journal:  Endocr Rev       Date:  2008-10-29       Impact factor: 19.871

2.  Metabolic syndrome does not impair the response to alfuzosin treatment in men with lower urinary tract symptoms: a double-blind, randomized, placebo-controlled study.

Authors:  Selçuk Altın; Tunç Ozan; Selçuk İlhan; Nevin İlhan; Rahmi Onur
Journal:  Turk J Urol       Date:  2015-09

3.  Prevalence of metabolic syndrome and degree of cardiovascular disease risk in patients with Psoriatic Arthritis.

Authors:  Sıdıka Gülkan Özkan; Hatice Yazısız; Ahmet Behlül; Yüksel Aslı Gökbelen; Fatih Borlu; Veli Yazısız
Journal:  Eur J Rheumatol       Date:  2017-03-01

4.  The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia: findings from a cohort in Turkey.

Authors:  M K Yazici; A E Anil Yağcioğlu; A Ertuğrul; N Eni; S Karahan; E Karaağaoğlu; S L Tokgözoğlu
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-06-03       Impact factor: 5.270

5.  Evidence for elevated (LIMK2 and CFL1) and suppressed (ICAM1, EZR, MAP2K2, and NOS3) gene expressions in metabolic syndrome.

Authors:  Suzan Tabur; Serdar Oztuzcu; Elif Oguz; Seniz Demiryürek; Hasan Dagli; Belgin Alasehirli; Mesut Ozkaya; Abdullah T Demiryürek
Journal:  Endocrine       Date:  2016-03-08       Impact factor: 3.633

6.  Incidence and trend of a metabolic syndrome phenotype among Tehranian adolescents: findings from the Tehran Lipid and Glucose Study, 1998-2001 to 2003-2006.

Authors:  Mohammad Afkhami-Ardekani; Saleh Zahedi-Asl; Maryam Rashidi; Mitra Atifah; Farhad Hosseinpanah; Fereidoun Azizi
Journal:  Diabetes Care       Date:  2010-06-02       Impact factor: 17.152

7.  Factor relationships of metabolic syndrome and echocardiographic phenotypes in the HyperGEN study.

Authors:  Pinchia Huang; Aldi T Kraja; Weihong Tang; Steven C Hunt; Kari E North; Cora E Lewis; Richard B Devereux; Giovanni de Simone; Donna K Arnett; Treva Rice; Dabeeru C Rao
Journal:  J Hypertens       Date:  2008-07       Impact factor: 4.844

8.  Are there any differences among psoriasis, psoriatic arthritis and rheumatoid arthritis in terms of metabolic syndrome and cardiovascular risk factors?

Authors:  Özlem Özkul; Ayten Yazıcı; Aysun S Aktürk; Duygu T Karadağ; Özlem O Işık; Senem Tekeoğlu; Ayşe Cefle
Journal:  Eur J Rheumatol       Date:  2018-10-01

Review 9.  Profile of hypertension in Turkey: from prevalence to patient awareness and compliance with therapy, and a focus on reasons of increase in hypertension among youths.

Authors:  Burak Pamukcu
Journal:  J Hum Hypertens       Date:  2021-01-18       Impact factor: 3.012

10.  The Changing Prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in Turkey in the Last Decade.

Authors:  Bülent Değertekin; Nurdan Tozun; Figen Demir; Gizem Söylemez; Şirin Parkan; Ezgi Gürtay; Deniz Mutlu; Meltem Toraman; Tolga Hayrettin Seymenoğlu
Journal:  Turk J Gastroenterol       Date:  2021-03       Impact factor: 1.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.